CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Published: 17 Jun 2020
Views: 765
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.
Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.
Related Videos
Latest data for managing ALK NSCLC patients
Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea
11 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-sma...
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
Why the ADAURA study is a big step forward for NSCLC
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
